Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Longbio Pharma (Suzhou) CoHKSE:01779 +5.51%10 Return-on-Tangible-Equity is 0.00% as of Dec. 2025. GuruFocus rates HKSE:01779 with a GF Score™ of 10/100. Among 1,196 Biotechnology companies, Longbio Pharma (Suzhou) Co ranks worse than 83611.96% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Longbio Pharma (Suzhou) Co's annualized net income for the quarter that ended in Dec. 2025 was HK$-193.97 Mil. Longbio Pharma (Suzhou) Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was HK$-98.70 Mil. Therefore, Longbio Pharma (Suzhou) Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was N/A%.
The historical rank and industry rank for Longbio Pharma (Suzhou) Co's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:01779's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -43.11 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Longbio Pharma (Suzhou) Co (HKSE:01779) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Longbio Pharma (Suzhou) Co Return-on-Tangible-Equity Related Terms
Longbio Pharma (Suzhou) Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longbio Pharma (Suzhou) Co Return-on-Tangible-Equity Chart
Longbio Pharma (Suzhou) Co Annual Data
Trend
Dec24
Dec25
Return-on-Tangible-Equity
0.00
0.00
Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24
Dec25
Return-on-Tangible-Equity
0.00
0.00
HKSE:01779 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Longbio Pharma (Suzhou) Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Longbio Pharma (Suzhou) Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Longbio Pharma (Suzhou) Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Longbio Pharma (Suzhou) Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a Return-on-Tangible-Equity of 0.00% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Longbio Pharma (Suzhou) Co and its competitors. According to the industry distribution chart, Longbio Pharma (Suzhou) Co ranks #999999 out of 1196 companies in the Biotechnology industry.
Is Longbio Pharma (Suzhou) Co's Return-on-Tangible-Equity too high?
Longbio Pharma (Suzhou) Co's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Longbio Pharma (Suzhou) Co ranks #999999 out of 1196 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Longbio Pharma (Suzhou) Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Longbio Pharma (Suzhou) Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Longbio Pharma (Suzhou) Co ranks #999999 out of 1196 companies for Return-on-Tangible-Equity. This places Longbio Pharma (Suzhou) Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Longbio Pharma (Suzhou) Co and its competitors. Longbio Pharma (Suzhou) Co's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longbio Pharma (Suzhou) Co stock overvalued right now?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Longbio Pharma (Suzhou) Co's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Longbio Pharma (Suzhou) Co (HKSE:01779), the current Return-on-Tangible-Equity is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score
Get the complete analysis for HKSE:01779
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01779 has been successfully added to your 
